194 related articles for article (PubMed ID: 32814846)
1. Treatment of metastatic castration resistant prostate cancer with radium-223: a retrospective study at a US tertiary oncology center.
McKay RR; Silver R; Bhak RH; Korves C; Cheng M; Appukkuttan S; Simmons SJ; Duh MS; Taplin ME
Prostate Cancer Prostatic Dis; 2021 Mar; 24(1):210-219. PubMed ID: 32814846
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes, management, and treatment patterns in patients with metastatic castration-resistant prostate cancer treated with radium-223 in community compared to academic settings.
Sartor O; Appukkuttan S; Weiss J; Tsao CK
Prostate; 2021 Jul; 81(10):657-666. PubMed ID: 33978244
[TBL] [Abstract][Full Text] [Related]
3. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
[TBL] [Abstract][Full Text] [Related]
4. A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.
Kim SI; Szeto AH; Morgan KP; Brower B; Dunn MW; Khandani AH; Godley PA; Rose TL; Basch EM; Milowsky MI; Whang YE; Crona DJ
PLoS One; 2021; 16(6):e0253021. PubMed ID: 34153052
[TBL] [Abstract][Full Text] [Related]
5. A randomized phase IIa study of quantified bone scan response in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with radium-223 dichloride alone or in combination with abiraterone acetate/prednisone or enzalutamide.
Petrylak DP; Vaishampayan UN; Patel KR; Higano CS; Albany C; Dawson NA; Mehlhaff BA; Quinn DI; Nordquist LT; Wagner VJ; Siegel J; Trandafir L; Sartor O
ESMO Open; 2021 Apr; 6(2):100082. PubMed ID: 33744812
[TBL] [Abstract][Full Text] [Related]
6. Radium-223 outcomes after multiple lines of metastatic castration-resistant prostate cancer therapy in clinical practice: implication of pre-treatment spinal epidural disease.
Spratt DE; Osborne JR; Zumsteg ZS; Rebeiz K; Leeman J; Rivera A; Morris MJ; Zelefsky MJ
Prostate Cancer Prostatic Dis; 2016 Sep; 19(3):271-6. PubMed ID: 27112529
[TBL] [Abstract][Full Text] [Related]
7. Disease Characteristics and Completion of Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer Treated With Radium-223 in an International Early Access Program.
Saad F; Gillessen S; Heinrich D; Keizman D; O'Sullivan JM; Nilsson S; Miller K; Wirth M; Reeves J; Seger M; Carles J; Heidenreich A
Clin Genitourin Cancer; 2019 Oct; 17(5):348-355.e5. PubMed ID: 31311763
[TBL] [Abstract][Full Text] [Related]
8. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
9. Optimal usage of radium-223 in metastatic castration-resistant prostate cancer.
Cha TL; Wu TT; Vogelzang NJ; Huang CY; Huang SP; Lin CC; Ou YC; Pang ST; Shen DH; Wu WJ; Chang WY
J Formos Med Assoc; 2017 Nov; 116(11):825-836. PubMed ID: 29046247
[TBL] [Abstract][Full Text] [Related]
10. Three-year follow-up of a phase II study of radium-223 dichloride in Japanese patients with symptomatic castration-resistant prostate cancer and bone metastases.
Uemura H; Uemura H; Nagamori S; Wakumoto Y; Kimura G; Kikukawa H; Yokomizo A; Mizokami A; Kosaka T; Masumori N; Kawasaki Y; Yonese J; Nasu Y; Fukasawa S; Sugiyama T; Kinuya S; Hosono M; Yamaguchi I; Akagawa T; Matsubara N
Int J Clin Oncol; 2019 May; 24(5):557-566. PubMed ID: 30875000
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases.
Wen L; Yao J; Valderrama A
J Manag Care Spec Pharm; 2019 Mar; 25(3-b Suppl):S1-S11. PubMed ID: 30827188
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
13. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
[TBL] [Abstract][Full Text] [Related]
14. Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC.
Sartor O; George D; Tombal B; Agarwal N; Higano CS; Sternberg CN; Miller K; Jiao X; Guo H; Sandström P; Bruno A; Verholen F; Saad F; Shore N
Future Oncol; 2022 Jan; 18(1):35-45. PubMed ID: 34636627
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of Combination Therapy With Radium-223 and Enzalutamide in Castration-resistant Prostate Cancer With Bone Metastases.
Wakita N; Hara T; Suzuki K; Terakawa T; Teishima J; Nakano Y; Miyake H
Anticancer Res; 2024 Jun; 44(6):2627-2635. PubMed ID: 38821616
[TBL] [Abstract][Full Text] [Related]
16. Survival outcomes in patients with chemotherapy-naive metastatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate.
Tagawa ST; Ramaswamy K; Huang A; Mardekian J; Schultz NM; Wang L; Sandin R; Lechpammer S; George DJ
Prostate Cancer Prostatic Dis; 2021 Dec; 24(4):1032-1040. PubMed ID: 33612825
[TBL] [Abstract][Full Text] [Related]
17. Sequencing Life-Prolonging Agents in Castration-Resistant Prostate Cancer Patients: Comparison of Sequences With and Without
Caffo O; Frantellizzi V; Monari F; Galli L; Costa RP; Pinto C; Tucci M; Baldari S; Facchini G; Bortolus R; Alongi F; Alongi P; Donner D; Fanti S; Sbrana A; Morabito A; Masini C; Zichi C; Pignata S; Borsatti E; Salgarello M; Spada M; De Giorgi U; Lo Re G; Cortesi E; De Vincentis G
Cancer Biother Radiopharm; 2021 Jun; 36(5):391-396. PubMed ID: 33769088
[No Abstract] [Full Text] [Related]
18. Economic Outcomes in Patients with Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide or Abiraterone Acetate Plus Prednisone.
Ramaswamy K; Lechpammer S; Mardekian J; Huang A; Schultz NM; Sandin R; Wang L; Baser O; George DJ
Adv Ther; 2020 May; 37(5):2083-2097. PubMed ID: 32112280
[TBL] [Abstract][Full Text] [Related]
19. Results From a Large, Multicenter, Retrospective Analysis On Radium223 Use in Metastatic Castration-resistant Prostate Cancer (mCRPC) in the Triveneto Italian Region.
Maruzzo M; Basso U; Borsatti E; Evangelista L; Alongi F; Caffo O; Maines F; Galuppo S; De Vivo R; Zustovich F; Palleschi D; Zivi A; Sava T; Sorarù M; Iacovelli R; Nicodemo M; Baier S; Fratino L; Zagonel V
Clin Genitourin Cancer; 2019 Feb; 17(1):e187-e194. PubMed ID: 30448106
[TBL] [Abstract][Full Text] [Related]
20. Impact of treatment delay in Radium-223 therapy of metastatic castration-resistant prostate cancer patients.
Fosbøl MØ; Petersen PM; Daugaard G; Holm S; Kjaer A; Mortensen J
Ann Nucl Med; 2018 Jan; 32(1):16-21. PubMed ID: 28975586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]